Field of Vision
Copyright ©The Author(s) 2022. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Clin Oncol. Aug 24, 2022; 13(8): 663-674
Published online Aug 24, 2022. doi: 10.5306/wjco.v13.i8.663
Potential of mRNA vaccines to become versatile cancer vaccines
Shiu-Ying Tsao
Shiu-Ying Tsao, Department of Oncology, Hong Kong SAR Oncology Centre, Hong Kong SAR 999077, China
Author contributions: Tsao SY designed the plan of the article, performed the reference search, wrote the manuscript, and has read and approved the final manuscript.
Conflict-of-interest statement: No conflict of interest is declared.
Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See:
Corresponding author: Shiu-Ying Tsao, MBBS, Academic Research, Department of Oncology, Hong Kong SAR Oncology Centre, 12/F McDonald's Building, 46-54 Yee Wo Street, Hong Kong SAR 999077, China.
Received: March 29, 2022
Peer-review started: March 29, 2022
First decision: May 31, 2022
Revised: June 15, 2022
Accepted: July 25, 2022
Article in press: July 25, 2022
Published online: August 24, 2022
Core Tip

Core Tip: Although vaccines are effective for pathogen prevention and cancers, hitherto, oncology vaccines have not yet made a very significant clinical impact. Currently, as mRNA vaccines already have a proven safety profile, it is highly appropriate to further develop the decades-old mRNA technology for oncology. Compared to other approved cancer vaccines, oncology mRNA vaccines may be more versatile, pragmatic, affordable, and effective. To combat the notoriously resistant tumor microenvironment, the probable mutual enhancement effects with, e.g., metronomic chemotherapy should be fully explored, especially as no significant added toxicity is anticipated. Clearly, undertaking much more research work (especially clinical) is mandatory.